VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Radiation exposure of hemophiliacs after radiosynoviorthesis with 186Re colloid
    Grmek, Marko ...
    Very limited data are available in the literature on the doses of unwanted radiation that patients receive following treatment with radiosynoviorthesis (RSO). Objective: The aim of this study was to ... assess the radiation exposure after RSO with 186Re colloid in hemophiliacs. Methods: This study involved 12 hemophiliacs why were treated for hemophilic joint disease with 14 RSOs by using 186Re colloid. Whole-body scintigrams were performed 1,6, and 24 hours and 3 and 7 days after RSO. Measurements, using a whole-body counter, were dove inunediately af'ter scintigraphv. with the treated joint protected with alead shield. The cumulative activity of 186Re in the body anal in the lymph nodes was calculated. the džstribution of 186Re in the body was determined by using the values for small colloids as proposed by the International Commission on Radiological Protection (ICRP) Publication 53. The computer code, OLINDA/EXM (Vanrterbilt University, Nashville, TN), was used for the calculation of the internal dose. A constant distance of 1 m between the anklejoint and body organs, and of 0.33 m between the elbow or shoulder joint and body organs, was used to calculate the contribution of gamma radiation to the effective radiation dose. Results: The mean effective dose received by hemophiliacs after RSO with 186Re colloid was 28 +- 9 microSv/MBq of the activity injected into the joint. The patients received 0.8-3.7 mSv (1.9 +- 0.8 mSv) owing to the leakage of 186Re from the treated joint and its retention in the body. The highest doses were established in the spleen (26.0 +- 10.7 mGy), the liver (17.6 +- 7.2 mGy), and red marrow (3.0 +- 0.8 mGy). The contribution of garrcma radiation to the effective dose was less than 0.1 mSv in RSO of the ankle, 0.4 mSv in the elbow, and 0.6 mSv in the shoulder joint treadnent. (Abstract truncated at 2000 characters)
    Vir: Cancer biotherapy & radiopharmaceuticals. - ISSN 1084-9785 (Letn. 22, št. 3, 2007, str. 417-422)
    Vrsta gradiva - članek, sestavni del
    Leto - 2007
    Jezik - angleški
    COBISS.SI-ID - 22996953

Vnos na polico